A randomized, open-label, controlled, multi-centre pilot study evaluating the efficacy and safety of Tenofovir 300 mg PO in combination with peginterferon alpha-2a subcutaneous 180 micrograms for 48 weeks in patients with HBeAg-positive CHB

Trial Profile

A randomized, open-label, controlled, multi-centre pilot study evaluating the efficacy and safety of Tenofovir 300 mg PO in combination with peginterferon alpha-2a subcutaneous 180 micrograms for 48 weeks in patients with HBeAg-positive CHB

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2013 Interim results (n=15) presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 03 Nov 2013 To date 27 patients have been enrolled according to an abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases
    • 22 Mar 2011 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top